NeuroSense Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRSN research report →
About the company
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).
- CEO
- Alon Ben-Noon
- IPO
- 2021
- Employees
- 17
- HQ
- Herzliya, IL
Price Chart
- Market Cap
- $17.46M
- P/E
- -2.64
- P/S
- 0.00
- P/B
- -11.53
- EV/EBITDA
- -2.71
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 173600.00%
- ROIC
- 464.96%
- Revenue
- $0 · 0.00%
- Net Income
- $-11,125,000 · -8.96%
- EPS
- $-0.44 · 20.00%
- Op Income
- $-11,085,000
- FCF YoY
- 24.26%
- 52W High
- $2.19
- 52W Low
- $0.63
- 50D MA
- $0.79
- 200D MA
- $0.93
- Beta
- 1.54
- Avg Volume
- 165.72K
Get TickerSpark's AI analysis on NRSN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Ben-Noon Alon | buy | 250,000 |
| Jun 16, 26 | Eisenberg Or | buy | 250,000 |
| Mar 26, 26 | Eisenberg Or | other | 200,000 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Jul 1, 21 | Eisenberg Or | other | 21,000 |
| Aug 15, 24 | Eisenberg Or | other | 66,666 |
| Mar 18, 26 | Mandil-Levin Revital | other | 0 |
| Mar 18, 26 | Mandil-Levin Revital | other | 0 |
Our NRSN coverage
Recent articles, reports, and earnings notes.
No research on NRSN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRSN report →Similar companies
Peers in the same neighborhood.